AH
ABCL icon

Andreas Halvorsen’s AbCellera Biologics ABCL Stock Holding History

Andreas Halvorsen’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,083,744
Closed -$648M – 89
2021
Q1 		$648M Sell
19,083,744
-200,000
-1% -$7.97M 1.93% 19
2020
Q4 		$776M Buy
+19,283,744
New +$882M 2.13% 12

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Andreas Halvorsen's ABCL Position: Q2 2021 in Review

Andreas Halvorsen sold out of AbCellera Biologics (ABCL) in Q2 2021, closing a stake of 19,083,744 shares — an estimated $648M sold.

Andreas Halvorsen first reported a position in ABCL in Q4 2020 and held it in 2 quarters. The position peaked at $776M in Q4 2020. 114 funds tracked by Wall St. Rank hold ABCL as of Q2 2021.

  • Andreas Halvorsen reported no remaining AbCellera Biologics position as of Q2 2021 after selling out during the quarter.
  • Andreas Halvorsen sold 19,083,744 AbCellera Biologics shares in Q2 2021, an estimated $648M.
  • Andreas Halvorsen first reported a position in AbCellera Biologics in Q4 2020 and held it in 2 quarters.
  • Andreas Halvorsen's AbCellera Biologics position peaked at $776M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2021.

Based on Viking Global Investors's 13F filing for Q2 2021, filed 16 Aug 2021.